Literature DB >> 31009073

Using a surrogate marker for early testing of a treatment effect.

Layla Parast1, Tianxi Cai2, Lu Tian3.   

Abstract

The development of methods to identify, validate, and use surrogate markers to test for a treatment effect has been an area of intense research interest given the potential for valid surrogate markers to reduce the required costs and follow-up times of future studies. Several quantities and procedures have been proposed to assess the utility of a surrogate marker. However, few methods have been proposed to address how one might use the surrogate marker information to test for a treatment effect at an earlier time point, especially in settings where the primary outcome and the surrogate marker are subject to censoring. In this paper, we propose a novel test statistic to test for a treatment effect using surrogate marker information measured prior to the end of the study in a time-to-event outcome setting. We propose a robust nonparametric estimation procedure and propose inference procedures. In addition, we evaluate the power for the design of a future study based on surrogate marker information. We illustrate the proposed procedure and relative power of the proposed test compared to a test performed at the end of the study using simulation studies and an application to data from the Diabetes Prevention Program.
© 2019 The International Biometric Society.

Entities:  

Keywords:  kernel smoothing; nonparametric method; resampling; surrogate; survival analysis; testing

Year:  2019        PMID: 31009073      PMCID: PMC6810708          DOI: 10.1111/biom.13067

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  23 in total

1.  Comparing biomarkers as principal surrogate endpoints.

Authors:  Ying Huang; Peter B Gilbert
Journal:  Biometrics       Date:  2011-04-22       Impact factor: 2.571

2.  The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

Authors:  A Ramachandran; C Snehalatha; S Mary; B Mukesh; A D Bhaskar; V Vijay
Journal:  Diabetologia       Date:  2006-01-04       Impact factor: 10.122

3.  Counterfactual links to the proportion of treatment effect explained by a surrogate marker.

Authors:  Jeremy M G Taylor; Yue Wang; Rodolphe Thiébaut
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

4.  Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy.

Authors:  Erin E Gabriel; Peter B Gilbert
Journal:  Biostatistics       Date:  2013-12-13       Impact factor: 5.899

5.  Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.

Authors:  Anna S C Conlon; Jeremy M G Taylor; Michael R Elliott
Journal:  Biostatistics       Date:  2013-11-26       Impact factor: 5.899

6.  Statistical validation of intermediate endpoints for chronic diseases.

Authors:  L S Freedman; B I Graubard; A Schatzkin
Journal:  Stat Med       Date:  1992-01-30       Impact factor: 2.373

7.  Meta-analysis for the evaluation of potential surrogate markers.

Authors:  M J Daniels; M D Hughes
Journal:  Stat Med       Date:  1997-09-15       Impact factor: 2.373

8.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

9.  Surrogate markers of insulin resistance: A review.

Authors:  Bhawna Singh; Alpana Saxena
Journal:  World J Diabetes       Date:  2010-05-15

10.  The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects.

Authors:  Luis E Simental-Mendía; Martha Rodríguez-Morán; Fernando Guerrero-Romero
Journal:  Metab Syndr Relat Disord       Date:  2008-12       Impact factor: 1.894

View more
  2 in total

1.  Estimation of the proportion of treatment effect explained by a high-dimensional surrogate.

Authors:  Ruixuan Rachel Zhou; Sihai Dave Zhao; Layla Parast
Journal:  Stat Med       Date:  2022-02-21       Impact factor: 2.497

2.  Testing for heterogeneity in the utility of a surrogate marker.

Authors:  Layla Parast; Tianxi Cai; Lu Tian
Journal:  Biometrics       Date:  2021-12-07       Impact factor: 1.701

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.